1.1k citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Carnegie Mellon UniversityUS3 papers
- Eli Lilly (United States)US3 papers
- Harvard UniversityUS3 papers
- New Jersey Institute of TechnologyUS3 papers
- Pfizer (United States)US3 papers
- United States Military AcademyUS3 papers
- University of WashingtonUS3 papers
- Centre National de la Recherche ScientifiqueFR2 papers
- Duke UniversityUS2 papers
- Janssen Research & Development (United States)US2 papers
- Nektar Therapeutics (United States)US2 papers
- New York UniversityUS2 papers
Showing 2020 · q-bio.OTShow all
2 papers · 2 filters
q-bio.OT2020★ 36 cited
Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu +10
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and it…
q-bio.OT2020
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19
Mary Nilsson, Brenda Crowe, Greg Anglin +4
In this paper, we provide guidance on how standard safety analyses and reporting of clinical trial safety data may need to be modified, given the potential impact of the COVID-19 p…